Showing results (931-940 of 1,842) with videos related to
Sort By:
Pageof 185
ESMO Open|April 12, 2025
Retrospective multicentric survival analysis of patients receiving TPEx regimen as first-line treatment of recurrent and/or metastatic head and neck squamous cell carcinomaL Libert, C Abdeddaim, K Saleh, et al.ESMO Open|April 3, 2025
Practical cancer nutrition, from guidelines to clinical practice: a digital solution to patient-centred careK S Hustad, L H Koteng, A Urrizola, et al.ESMO Open|April 3, 2025
LUDICAS: sexual dysfunction in patients with lung cancer, a multicenter cross-sectional studyA V Ospina-Serrano, A Collazo-Lorduy, E Azkona-Uribelarrea, et al.ESMO Open|April 5, 2025
Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudyA C Chiang, M E Olmedo Garcia, J W Carlisle, et al.ESMO Open|April 25, 2025
Tumor-informed ctDNA assay to predict recurrence in locally advanced squamous-cell carcinoma of the head and neck (SCCHN)N Honoré, G Laliotis, V Aushev, et al.ESMO Open|April 25, 2025
Extended adjuvant endocrine therapy in early breast cancer: finding the individual balanceS Lobo-Martins, L Arecco, T P Cabral, et al.ESMO Open|June 14, 2025
Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2- early breast cancer: a United States Electronic Health Records database analysisP Tarantino, H S Rugo, G Curigliano, et al.ESMO Open|June 13, 2025
Clinical characterization of FGFR2b expression in patients with advanced gastric or gastroesophageal junction adenocarcinomaS Sato, S L Rhodes, Y Aoki, et al.ESMO Open|May 29, 2025
Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trialX Hu, G Curigliano, K Yonemori, et al.Pageof 185